U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938724) titled 'Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer' on April 07.
Brief Summary: HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatment...